Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 1 2000
Play
Audio Below:
It is relatively inert compound, that it doesn’t have its own
intrinsic any hormonal property. So it didn’t have any thromboembolic
complication, which was seen with the tamoxifen. It almost to 50%
lowered risk of thromboembolic complications and also since it doesn’t
have an agonistic effect on the endometrium,- so that the risk of
vaginal bleeding in a postmenopausal woman which causes quite a
bit, even though we think it is a minor inconvenience. But when
a woman has postmenopausal bleeding it requires extensive evaluation;
number of times patients are having pap smear, patient may need
endometrial biopsy, patients get ultrasound and all kind of things
to make sure the patient doesn’t have endometrial cancer, and
those are also substantially reduced.
